Applications of metabolomics for kidney disease research: From biomarkers to therapeutic targets

Hiromi I. Wettersten, Robert H Weiss

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Metabolomics is one of the relative newcomers of the omics techniques and is likely the one most closely related to actual real-time disease pathophysiology. Hence, it has the power to yield not only specific biomarkers but also insight into the pathophysiology of disease. Despite this power, metabolomics as applied to kidney disease is still in its early adolescence and has not yet reached the mature stage of clinical application, i.e., specific biomarker and therapeutic target discovery. On the other hand, the insight gained from hints into what makes these diseases tick, as is evident from the metabolomics pathways which have been found to be altered in kidney cancer, are now beginning to bear fruit in leading to potential therapeutic targets. It is quite likely that, with greater numbers of clinical materials and with more investigators jumping into the field, metabolomics may well change the course of kidney disease research.

Original languageEnglish (US)
Pages (from-to)147-154
Number of pages8
JournalOrganogenesis
Volume9
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Metabolomics
Kidney Diseases
Biomarkers
Research
Kidney Neoplasms
Ticks
Therapeutics
Fruit
Fruits
Research Personnel

Keywords

  • Biomarker
  • Kidney disease
  • Metabolomics
  • Therapeutic target

ASJC Scopus subject areas

  • Developmental Biology
  • Embryology
  • Transplantation
  • Biomedical Engineering

Cite this

Applications of metabolomics for kidney disease research : From biomarkers to therapeutic targets. / Wettersten, Hiromi I.; Weiss, Robert H.

In: Organogenesis, Vol. 9, No. 1, 01.2013, p. 147-154.

Research output: Contribution to journalArticle

@article{fe787eefa45e460fa6ec7ab5db5c4689,
title = "Applications of metabolomics for kidney disease research: From biomarkers to therapeutic targets",
abstract = "Metabolomics is one of the relative newcomers of the omics techniques and is likely the one most closely related to actual real-time disease pathophysiology. Hence, it has the power to yield not only specific biomarkers but also insight into the pathophysiology of disease. Despite this power, metabolomics as applied to kidney disease is still in its early adolescence and has not yet reached the mature stage of clinical application, i.e., specific biomarker and therapeutic target discovery. On the other hand, the insight gained from hints into what makes these diseases tick, as is evident from the metabolomics pathways which have been found to be altered in kidney cancer, are now beginning to bear fruit in leading to potential therapeutic targets. It is quite likely that, with greater numbers of clinical materials and with more investigators jumping into the field, metabolomics may well change the course of kidney disease research.",
keywords = "Biomarker, Kidney disease, Metabolomics, Therapeutic target",
author = "Wettersten, {Hiromi I.} and Weiss, {Robert H}",
year = "2013",
month = "1",
doi = "10.4161/org.24322",
language = "English (US)",
volume = "9",
pages = "147--154",
journal = "Organogenesis",
issn = "1547-6278",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Applications of metabolomics for kidney disease research

T2 - From biomarkers to therapeutic targets

AU - Wettersten, Hiromi I.

AU - Weiss, Robert H

PY - 2013/1

Y1 - 2013/1

N2 - Metabolomics is one of the relative newcomers of the omics techniques and is likely the one most closely related to actual real-time disease pathophysiology. Hence, it has the power to yield not only specific biomarkers but also insight into the pathophysiology of disease. Despite this power, metabolomics as applied to kidney disease is still in its early adolescence and has not yet reached the mature stage of clinical application, i.e., specific biomarker and therapeutic target discovery. On the other hand, the insight gained from hints into what makes these diseases tick, as is evident from the metabolomics pathways which have been found to be altered in kidney cancer, are now beginning to bear fruit in leading to potential therapeutic targets. It is quite likely that, with greater numbers of clinical materials and with more investigators jumping into the field, metabolomics may well change the course of kidney disease research.

AB - Metabolomics is one of the relative newcomers of the omics techniques and is likely the one most closely related to actual real-time disease pathophysiology. Hence, it has the power to yield not only specific biomarkers but also insight into the pathophysiology of disease. Despite this power, metabolomics as applied to kidney disease is still in its early adolescence and has not yet reached the mature stage of clinical application, i.e., specific biomarker and therapeutic target discovery. On the other hand, the insight gained from hints into what makes these diseases tick, as is evident from the metabolomics pathways which have been found to be altered in kidney cancer, are now beginning to bear fruit in leading to potential therapeutic targets. It is quite likely that, with greater numbers of clinical materials and with more investigators jumping into the field, metabolomics may well change the course of kidney disease research.

KW - Biomarker

KW - Kidney disease

KW - Metabolomics

KW - Therapeutic target

UR - http://www.scopus.com/inward/record.url?scp=84876579151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876579151&partnerID=8YFLogxK

U2 - 10.4161/org.24322

DO - 10.4161/org.24322

M3 - Article

C2 - 23538740

AN - SCOPUS:84876579151

VL - 9

SP - 147

EP - 154

JO - Organogenesis

JF - Organogenesis

SN - 1547-6278

IS - 1

ER -